



FOR IMMEDIATE RELEASE.....

**NanoBioMagnetics CEO to Speak at
National NanoBusiness Alliance Conference**

Edmond, OK (April 28, 2008): Officials at NanoBioMagnetics, Inc (NBMI) announced today that Founder and CEO, Charles Seeney, has been invited to speak at the upcoming NanoBusiness Alliance Conference to be held in New York City on May 4 – 6. The NBMI presentation will be part of a section titled “Spotlight on Oklahoma”, and will present an overview of the company’s developing business program and progress to date with regard to its technologies for magnetically vectored therapeutics.

The NanoBusiness Alliance is a not-for-profit association dedicated to promoting the commercialization of nanotechnology and helping companies bring affordable, life-improving nanotech products to the market. The Alliance actively represents members on Capitol Hill in order to create a positive policy climate for nanotechnology, and also on Wall Street where the global financial community can focus on this high-potential sector and the Alliance member companies. The Annual NanoBusiness Alliance Conference provides forums for the international financial community to review investment opportunities.

“This is an excellent forum for us to present NBMI’s program for validation and commercialization of our Organ-Assisting-Device (OAD) healthcare applications”, says Seeney. He goes on to point out that NBMI’s OAD technologies are based on a magnetic vectoring methodology in which magnetic nanoparticles are used to target therapeutics site-specifically. NBMI’s OAD applications are developed and validated in collaborations with major research institutions; for example, a collaboration evaluating the tumor-specific delivery of chemotherapeutics is in progress with scientists at the M. D. Anderson Cancer Institute. The company also recently announced the award of a US Patent where magnetic nanoparticles are components of middle ear hearing devices, which was accomplished in collaboration with scientists at the Massachusetts Eye and Ear Infirmary, Affiliate of Harvard Medical School.

Seeney goes on to discuss some details of his presentation, which will focus on the commercialization potential of the company’s OAD technologies. Following technical validation of specific OAD healthcare applications, the company’s business model calls for the spin-off of business units with pharmaceutical partners for manufacture and commercialization. The company’s first spin-off, now in progress, is the XetaComp Nanotechnology business unit, which is producing functionalized nanomaterials at a nanofabrication facility in Lawton, OK. The business unit recently was awarded its second nanotechnology commercialization grant from the State of Oklahoma. A second spin-off, the OAD Technology for the Tumor Specific Delivery of Paclitaxel, is being projected within the next 12 – 18 months.

Nanobiomagnetics, a segment of the emerging field of nanomedicine, is growing rapidly, receiving greater scientific interest as the potential for such functionalized nanomaterials becomes apparent. NBMI intends to continue to play a central role in the development of this industry segment.

Contact: Charles E Seeney
(405) 844-5118

nanobio@nanobmi.com